Living with HIV has changed dramatically over the past several decades. Modern antiretroviral therapy (ART) can suppress HIV to very low levels, protect immune-system function, reduce the risk of HIV-related illness, and allow many people living with HIV to lead long and healthy lives.
Treatment has also become more convenient. Single-tablet regimens, simplified combinations, and long-acting injectable medicines have reduced some of the daily treatment burdens associated with earlier HIV therapies. At the same time, HIV care now places greater emphasis on overall health, mental well-being, medication adherence, prevention, and management of other medical conditionsThere is still no cure that removes HIV from the body, so treatment remains a lifelong part of HIV care. However, effective treatment can transform HIV from a potentially life-threatening infection into a manageable chronic condition.
HIV attacks cells that are important to immune-system function, particularly CD4 cells. Without treatment, HIV can gradually weaken the immune system and increase the risk of infections and other serious illnesses.
ART works by using combinations of medicines that interfere with different stages of the HIV life cycle. The goal is to prevent HIV from multiplying and to reduce the amount of virus in the blood.
This amount is called the viral load. When treatment reduces viral load to a very low level, the immune system can function more effectively and the risk of HIV-related complications declines.
Viral suppression is generally defined as having fewer than 200 copies of HIV per milliliter of blood. An undetectable viral load means the amount of HIV is below the level that a standard laboratory test can detect.
Current medical guidance recommends ART for everyone diagnosed with HIV, regardless of how long the infection has been present or how healthy the person feels.
Treatment is generally recommended as soon as possible after diagnosis. Starting therapy early can help protect the immune system, reduce the risk of HIV-related complications, and lower the possibility of sexual transmission after viral suppression is achieved.
The first treatment plan depends on several factors, including:
The September 2026 U.S. HIV treatment guidelines continue to recommend second-generation integrase strand transfer inhibitor-based regimens for most people beginning ART. Recommended approaches include bictegravir with tenofovir alafenamide and emtricitabine, or dolutegravir-based combinations. Dolutegravir/lamivudine is also recommended in selected circumstances when specific clinical requirements are met.
One major development in HIV care has been the simplification of treatment.
Many modern regimens combine multiple medicines into a single tablet taken once per day. This can reduce pill burden and make treatment routines easier to maintain.
Single-tablet therapy does not mean every person with HIV should use the same medicine. HIV treatment must be individualized because medical history, resistance patterns, hepatitis B infection, kidney or bone concerns, pregnancy considerations, other medications, and other factors can influence regimen selection.
The 2026 NIH guidelines specifically emphasize factors such as effectiveness, tolerability, pill burden, dosing frequency, drug interactions, cost, access, resistance testing, and other medical conditions when selecting ART.
Another significant development is long-acting injectable treatment.
Instead of taking HIV medicine every day, certain people can receive treatment through injections administered by a healthcare professional. Depending on the medicine and treatment plan, injections may be given monthly or every other month.
For example, cabotegravir and rilpivirine can be used as a long-acting treatment regimen for certain adults whose HIV is already suppressed. Current guidance generally considers long-acting treatment for people who have maintained viral suppression, have no history of treatment failure, and do not have an allergy to the medicines involved.
Long-acting treatment can be particularly useful for people who find daily pills difficult to maintain. However, injections require regular healthcare appointments, making consistent clinic attendance important.
Missing scheduled injections should be discussed promptly with the healthcare team because prolonged gaps can increase the risk of loss of viral suppression and drug resistance.
HIV treatment continues to evolve rapidly.
In August 2026, the U.S. Food and Drug Administration approved bictegravir/lenacapavir, marketed as Bixlenvo, for HIV treatment. The September 2026 NIH guideline update notes the approval but also states that the expert guideline panel is reviewing the information for a future guideline update.
This distinction is important. FDA approval and inclusion in detailed clinical guidelines are related but separate processes. New medicines can enter clinical practice while expert panels continue evaluating how they fit into broader treatment recommendations.
The development also illustrates how HIV treatment research continues to focus on durable viral suppression, simplified treatment, resistance management, and reduced treatment burden.
Viral suppression is one of the most important goals of HIV treatment.
When ART is taken consistently, HIV replication can be reduced to very low levels. This protects immune function and reduces the likelihood of developing serious HIV-related illnesses.
Maintaining an undetectable viral load also has an important prevention benefit.
The principle known as U=U, or Undetectable = Untransmittable, means that people living with HIV who maintain an undetectable viral load through effective treatment do not transmit HIV through sex. This conclusion is supported by extensive scientific evidence and is now a central part of modern HIV care and prevention.
U=U does not mean HIV has been eliminated from the body. Treatment must continue to maintain viral suppression.
Adherence remains one of the foundations of successful HIV treatment.
Taking HIV medicine according to the prescribed schedule helps keep viral load suppressed. Repeated missed doses can allow HIV to multiply and may increase the possibility of developing drug resistance.
Drug resistance occurs when HIV changes in ways that allow it to survive exposure to particular medicines. Resistant HIV can make some treatments less effective and may limit future treatment choices.
Adherence difficulties can have many causes, including:
Treatment plans can sometimes be adjusted when these challenges arise. Speaking with an HIV clinician, pharmacist, nurse, or case manager can help identify practical solutions.
HIV treatment involves more than receiving a prescription.
Regular monitoring helps the healthcare team determine whether treatment is working and whether changes are necessary.
Two important measurements are viral load and CD4 count.
Viral load measures the amount of HIV in the blood.
A declining viral load generally indicates that treatment is working. Once viral suppression is achieved, ongoing testing helps determine whether suppression is being maintained.
CD4 cells are immune cells affected by HIV.
A higher CD4 count generally indicates stronger immune function. A very low CD4 count can increase the risk of opportunistic infections and other complications.
The frequency of testing depends on treatment history, viral suppression, overall health, and clinical circumstances.
Modern HIV medicines are generally well tolerated, but side effects can occur.
Possible effects vary considerably depending on the medication. Some may involve gastrointestinal symptoms, headaches, sleep changes, skin reactions, or metabolic changes.
The broader medication list also matters.
HIV medicines can interact with prescription medicines, over-the-counter drugs, supplements, and recreational substances. Certain medicines can change how HIV drugs are absorbed or metabolized.
For this reason, medication reviews should include all prescription medicines, nonprescription products, vitamins, and supplements.
Stopping ART without medical guidance can create problems, particularly if treatment interruption allows viral load to rise.
Modern HIV care increasingly focuses on whole-person health rather than HIV alone.
As people with HIV live longer, healthcare teams also manage conditions such as:
Some HIV medicines can influence metabolic, kidney, bone, or cardiovascular considerations. These factors may influence treatment selection.
The 2026 HIV guidelines emphasize evaluating comorbidities and other individual characteristics when selecting ART.
Hepatitis B is particularly important when selecting HIV treatment.
Some HIV medicines also have activity against hepatitis B. A regimen that is appropriate for HIV alone may not be appropriate for someone with chronic hepatitis B unless adequate hepatitis B treatment is included.
For example, the 2026 NIH guidelines specifically caution against using dolutegravir/lamivudine alone in people with hepatitis B coinfection unless another hepatitis-B-active medicine is included.
This is one reason laboratory testing and medical history are important before finalizing an ART regimen.
Resistance testing can provide important information about which HIV medicines are likely to work effectively.
Resistance may already be present when HIV is initially diagnosed, or it may develop after treatment exposure.
The treatment team may use resistance-test results when selecting an initial regimen or changing treatment after virologic failure.
A particularly important consideration involves previous exposure to long-acting cabotegravir used as PrEP. The 2026 NIH guidelines note that integrase resistance has occurred in people who acquired HIV after exposure to long-acting cabotegravir PrEP. In such circumstances, resistance testing can influence the initial treatment approach.